

Regioselective Synthesis of Oxazole Derivatives *via* Palladium-Catalyzed and Copper-Mediated Cascade Oxidative Cyclization

Jia Zheng, Min Zhang, Liangbin Huang, Xiaohan Hu, Wanqing Wu, Huawen Huang,
Huangfeng Jiang*

School of Chemistry and Chemical Engineering, South China University of Technology,

Guangzhou 510640, P. R. China

jianghf@scut.edu.cn

Supporting Information

A. General methods.....	S2
B. General procedure for the synthesis of oxazole derivatives.....	S2
C. Screening reaction conditions.....	S2
D. Control experiments.....	S4
E. Analytical data for 3aa-3pa	S5
F. Reference.....	S15
G. NMR Spectra.....	S16
H. X-ray Crystallographic Analysis.....	S48

A. General methods


^1H and ^{13}C NMR spectra were recorded on BRUKER DRX-400 spectrometer using CDCl_3 as solvent and TMS as an internal standard. Gas chromatograph mass spectra were obtained with a SHIMADZU model GCMS-QP5000 spectrometer.

B. General procedure for the synthesis of oxazole derivatives

Propargyl ester (0.5 mmol), benzylamine (0.75 mmol), H_2O (1.5 mmol) were added to 1.5 mL DMSO. Then $\text{Pd}(\text{CH}_3\text{CN})_2\text{Cl}_2$ (5 mol%) and CuBr_2 (2 equiv) were added and the mixture was stirred under air at $100\text{ }^\circ\text{C}$ for 8 h. After that, water was added and extracted with ethyl acetate twice. The combined organic phase was dried over Na_2SO_4 and concentrated. The residue was eventually purified by flash column chromatography (EtOAc: Petroleum=1:15) on a silica gel to afford the product.

C. Screening reaction conditions

Table 1. Survey of reaction conditions for reaction ^a



entry	catalyst	additive	solvent	yields ^b
1	$\text{Pd}(\text{OAc})_2$	-	DMF	N.D.
2	$\text{Pd}(\text{OAc})_2$	-	DMSO	3%
3	$\text{Pd}(\text{OAc})_2$	CuCl_2	DMSO	18%
4	-	CuCl_2	DMSO	Trace
5	$\text{Pd}(\text{OAc})_2$	K_2CO_3	DMSO	N.D.
6 ^c	$\text{Pd}(\text{OAc})_2$	DABCO	DMSO	N.D.
7 ^c	$\text{Pd}(\text{OAc})_2$	HOAc	DMSO	N.D.
8	$\text{Pd}(\text{OAc})_2$	ZnCl_2	DMSO	N.D.
9	$\text{Pd}(\text{OAc})_2$	FeCl_3	DMSO	N.D.
10	$\text{Pd}(\text{OAc})_2$	LiCl_2	DMSO	N.D.
11	$\text{Pd}(\text{OAc})_2$	CuCl_2	CH_3CN	N.D.
12	$\text{Pd}(\text{OAc})_2$	CuCl_2	1,4-Dioxane	N.R.
13	$\text{Pd}(\text{OAc})_2$	CuCl_2	THF	N.R.
14	$\text{Pd}(\text{OAc})_2$	CuCl_2	DCE	N.R.
15	$\text{Pd}(\text{OAc})_2$	CuCl_2	Toluene	N.D.
16	$\text{Pd}(\text{OAc})_2$	CuBr_2	DMSO	30%
17	$\text{Pd}(\text{OAc})_2$	$\text{Cu}(\text{OAc})_2$	DMSO	N.D.
18	$\text{Pd}(\text{OAc})_2$	$\text{Cu}(\text{OTf})_2$	DMSO	N.D.

19	Pd(OAc) ₂	CuF ₂	DMSO	N.D.
20	PdCl ₂	CuBr ₂	DMSO	52%
21	PdBr ₂	CuBr ₂	DMSO	50%
22	Pd(TFA) ₂	CuBr ₂	DMSO	23%
23	Pd(dba) ₂	CuBr ₂	DMSO	11%
24	Pd(PPh ₃) ₂ Cl ₂	CuBr ₂	DMSO	58%
25	Pd(CH ₃ CN) ₂ Cl ₂	CuBr ₂	DMSO	63%
26 ^c	Pd(CH ₃ CN) ₂ Cl ₂	CuBr ₂	DMSO	72%
27 ^d	Pd(CH ₃ CN) ₂ Cl ₂	CuBr ₂	DMSO	56%
28 ^{c, e}	Pd(CH ₃ CN) ₂ Cl ₂	CuBr ₂	DMSO	81% (75%) ^f
29 ^{c, e, g}	Pd(CH ₃ CN) ₂ Cl ₂	CuBr ₂	DMSO	80%
30 ^{c, e, h}	Pd(CH ₃ CN) ₂ Cl ₂	CuBr ₂	DMSO	N.P.
31 ^{c, e, i}	Pd(CH ₃ CN) ₂ Cl ₂	CuBr ₂	DMSO	78%
32 ^{c, e, j}	Pd(CH ₃ CN) ₂ Cl ₂	CuBr ₂	DMSO	39%


^a Reaction conditions: **1a** (0.5 mmol), **2a** (0.75 mmol), H₂O (1.5 mmol), catalyst (10 mol%) and additive (1equiv) in 1.5 mL of solvent under O₂ (1 atm) at 100 °C for 8 h. ^b Determined by GC. ^c 5 mol% of catalyst. ^d 2 mol% of catalyst. ^e 2 equiv of additive. ^f Isolated yield. ^g Under an air atmosphere. ^h at 50°C. ⁱ at 120°C. ^j Under an N₂ atmosphere.

We began our studies with the model reaction of ethyl phenylpropiolate (**1a**) and benzylamine (**2a**). With Pd(OAc)₂ as the catalyst under oxygen atmosphere (1 atm), no desired product was obtained in DMF while 3% yield of **3aa** in DMSO (Table 1, entries 1, 2). In order to optimize the conditions, different additives were tested and the yield of **3aa** was increased to 18% and 30% when CuCl₂ and CuBr₂ was used respectively (Table 1, entries 3 and 16). Palladium catalyst was crucial because we only got trace amount of product in the absence of palladium (Table 1, entry 4). Other additives showed no efficiency to this reaction (Table 1, entries 4-10, 17-19). Further investigation revealed that among the solvents we chose, this transformation could only go smoothly in DMSO (Table 1, entries 11-15). Subsequently, the effect of different palladium catalysts was surveyed (Table 1, entries 20-25). Pd(CH₃CN)₂Cl₂ turned to be an efficient catalyst and 63% yield of the product was achieved (Table 1, entry 25). When the amount of catalyst and additive switched to 5% and 2 equiv, 75% isolated yield of the corresponding product **3aa** could be obtained (Table 1, entries 26-28). Then we found it worked equally well when performed under air (Table 1, entry 29). However, oxygen also promoted this reaction since the yield decreased to 39% under argon atmosphere (Table 1, entry 32).

D. Control Experiments


Procedure for ^{18}O -labeling experiment

Ethyl phenylpropiolate **1a** (0.5 mmol), benzylamine **2a** (0.75 mmol), H_2^{18}O (1.5 mmol) were added to 1.5 mL DMSO. Then $\text{Pd}(\text{CH}_3\text{CN})_2\text{Cl}_2$ (5 mol%) and CuBr_2 (2 equiv) were added and the mixture was stirred under air at 100 °C for 8 h. Then, water was added to the mixture and extracted with ethyl acetate twice. The combined organic phase was dried over Na_2SO_4 and concentrated. The residue was eventually purified by flash column chromatography (EtOAc: Petroleum=1:15) on a silica gel to afford the product.




E. Analytical data for 3aa-3oa

ethyl 2,5-diphenyloxazole-4-carboxylate (3aa)¹




Yellow solid. M.p.: 70-71 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.08 (dd, *J* = 6.7, 2.9 Hz, 2H), 8.03 (dd, *J* = 7.9, 1.5 Hz, 2H), 7.50-7.32 (m, 6H), 4.38 (q, *J* = 7.1 Hz, 2H), 1.34 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (101 MHz, CDCl₃) δ 162.31, 159.84, 155.07, 131.06, 130.27, 128.81, 128.57, 128.40, 128.35, 127.18, 126.89, 126.44, 61.47, 14.29. ppm; MS (EI, 70 eV) *m/z*: 77, 105, 221, 293. IR (KBr): 3062, 2982, 1720, 1562, 1488, 1215, 1098, 1448, 1243, 1056, 928, 765, 710, 688.

ethyl 2-(4-fluorophenyl)-5-phenyloxazole-4-carboxylate (3ab)




Yellow solid. M.p.: 115-117 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.13-8.04 (m, 2H), 8.01 (dd, *J* = 7.8, 1.8 Hz, 2H), 7.47-7.38 (m, 3H), 7.10 (t, *J* = 8.7 Hz, 2H), 4.38 (q, *J* = 7.1 Hz, 2H), 1.34 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 164.5(d, *J* = 250 Hz), 162.2, 159.0, 155.1, 130.0, 129.1, 129.0, 128.4(d, *J* = 20 Hz), 128.3, 127.6, 122.8(d, *J* = 3 Hz), 116.1(d, *J* = 22 Hz), 61.5, 14.3ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ: -108.1 (m, 1F) ppm. MS (EI, 70 eV) *m/z*: 77, 105, 123, 239, 311. HRMS (ESI) *m/z*: calcd for C₁₈H₁₄FNNaO₃ [M+Na]⁺, 334.0850; found, 334.0863. IR (KBr): 3070, 2983, 1720, 1609, 1563, 1497, 1218, 1097, 824, 760, 692.

ethyl 2-(4-chlorophenyl)-5-phenyloxazole-4-carboxylate (3ac)²




White solid. M.p.: 100-102 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.19-7.99 (m, 4H), 7.53-7.41 (m, 5H), 4.44 (q, *J* = 7.1 Hz, 2H), 1.41 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 162.1, 158.8, 155.2, 137.3, 130.4, 129.2, 128.5, 128.4, 128.3, 128.1, 126.9, 124.9, 61.5, 14.3 ppm; MS (EI, 70 eV) *m/z*: 77, 105, 139, 255, 327. IR (KBr): 2983, 1719, 1495, 1269, 1213, 1092, 757.

ethyl 2-(4-bromophenyl)-5-phenyloxazole-4-carboxylate (3ad)




White solid. M.p.: 97-98 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.08 (dd, *J* = 7.7, 1.9 Hz, 2H), 8.01 (d, *J* = 8.6 Hz, 2H), 7.61 (d, *J* = 8.6 Hz, 2H), 7.53-7.43 (m, 3H), 4.45 (q, *J* = 7.1 Hz, 2H), 1.42 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 162.1, 158.9, 155.3, 132.1, 130.4, 128.6, 128.4, 128.2, 126.9, 125.7, 125.3, 61.5, 14.2 ppm; MS (EI, 70 eV) *m/z*: 77, 105, 182, 301, 371. HRMS (ESI) *m/z*: calcd for C₁₈H₁₄BrNNaO₃ [M+Na]⁺, 394.0049; found, 394.0026. IR (KBr): 2923, 1720, 1604, 1560, 1484, 1214, 1097, 1013, 822, 757, 692.

ethyl 2-(4-(trifluoromethyl)phenyl)-5-phenyloxazole-4-carboxylate (3ae)




White solid. M.p.: 101-103 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.17 (d, *J* = 8.2 Hz, 2H), 8.06-7.95 (m, 2H), 7.65 (d, *J* = 8.3 Hz, 2H), 7.46-7.32 (m, 3H), 4.37 (q, *J* = 7.1 Hz, 2H), 1.33 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 162.0, 158.3, 155.7, 132.5 (q, *J* = 33 Hz), 130.6, 129.6, 128.6, 128.5, 127.0, 126.8, 125.8 (q, *J* = 3.7 Hz), 125.1, 122.4, 61.6, 14.2 ppm. ¹⁹F NMR (376 MHz, CDCl₃) δ: -62.9 (s, 3F) ppm. MS (EI, 70 eV) *m/z*: 77, 105, 145, 173, 361. HRMS (ESI) *m/z*: calcd for C₁₉H₁₄F₃NNaO₃ [M+Na]⁺, 384.0818; found, 384.0823. IR (KBr): 2965, 1722, 1619, 1563, 1495, 1322, 1127, 847, 756, 709.

ethyl 5-phenyl-2-p-tolyloxazole-4-carboxylate (3af)³




White solid. M.p.: 84-86 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.15-8.07 (m, 2H), 8.04 (d, $J = 8.2$ Hz, 2H), 7.54-7.40 (m, 3H), 7.28 (d, $J = 8.0$ Hz, 2H), 4.45 (q, $J = 7.1$ Hz, 2H), 2.40 (s, 3H), 1.42 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) $\delta = 162.4, 160.1, 154.8, 141.5, 130.2, 129.5, 128.5, 128.4, 128.2, 127.2, 126.8, 123.7, 61.4, 21.6, 14.3$ ppm; MS (EI, 70 eV) m/z : 77, 91, 119, 235, 307. HRMS (ESI) m/z : calcd for $\text{C}_{19}\text{H}_{17}\text{NNaO}_3$ $[\text{M}+\text{Na}]^+$, 330.1101; found, 330.1102. IR (KBr): 2981, 2925, 1718, 1613, 1588, 1497, 1213, 1098, 1025, 760, 692.

ethyl 2-(4-methoxyphenyl)-5-phenyloxazole-4-carboxylate (3ag)³



Yellow solid. M.p.: 77-78 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.24-8.00 (m, 4H), 7.52 - 7.43 (m, 3H), 6.98 (d, $J = 8.8$ Hz, 2H), 4.45 (q, $J = 7.1$ Hz, 2H), 3.86 (s, 3H), 1.42 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) $\delta = 162.4, 161.9, 133.5, 130.1, 128.6, 128.5, 128.4, 128.3, 128.1, 127.3, 119.1, 114.3, 61.4, 55.4, 14.3$ ppm; MS (EI, 70 eV) m/z : 77, 105, 135, 207, 323. IR (KBr): 2983, 1718, 1613, 1499, 1256, 1096, 756.


ethyl 2-(3-methoxyphenyl)-5-phenyloxazole-4-carboxylate (3ah)



Orange solid. M.p.: 87-89 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.14-8.06 (m, 2H), 7.76-7.70 (m, 1H), 7.68 (dd, $J = 2.3, 1.6$ Hz, 1H), 7.54-7.45 (m, 3H), 7.39 (t, $J = 8.0$ Hz, 1H), 7.08-7.02 (m, 1H), 4.45 (q, $J = 7.1$ Hz, 2H), 3.89 (s, 3H), 1.42 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) $\delta = 162.3, 159.9, 159.8, 155.1, 130.3, 129.9, 128.6, 128.4, 128.3, 127.6, 127.1, 119.3, 117.7, 111.5, 61.5, 55.5, 14.3$ ppm; MS (EI, 70 eV)


m/z : 77, 105, 135, 207, 323. HRMS (ESI) m/z : calcd for $C_{19}H_{17}NNaO_4$ $[M+Na]^+$, 346.1050; found, 346.1046. IR (KBr): 2924, 1719, 1596, 1564, 1098, 1037, 757.

ethyl 2-(2-methoxyphenyl)-5-phenyloxazole-4-carboxylate (3ai)




Yellow oil. 1H NMR (400 MHz, $CDCl_3$) δ 8.21-8.14 (m, 2H), 8.06 (dd, $J = 7.7, 1.4$ Hz, 1H), 7.54-7.42 (m, 4H), 7.06 (dd, $J = 14.3, 7.8$ Hz, 2H), 4.47 (q, $J = 7.1$ Hz, 2H), 3.98 (d, $J = 1.0$ Hz, 3H), 1.44 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ 162.5, 158.6, 158.0, 154.7, 132.4, 130.7, 130.1, 128.5, 128.4, 128.0, 127.4, 120.6, 115.6, 111.9, 61.3, 56.0, 14.3 ppm; MS (EI, 70 eV) m/z : 77, 105, 135, 249, 323. HRMS (ESI) m/z : calcd for $C_{19}H_{17}NNaO_4$ $[M+Na]^+$, 346.1050; found, 346.1063. IR (KBr): 2960, 1719, 1590, 1563, 1488, 1215, 1101, 1023, 913, 746, 694.

ethyl 2-(2-bromophenyl)-5-phenyloxazole-4-carboxylate (3aj)



Yellow solid. M.p.: 64-65 °C. 1H NMR (400 MHz, $CDCl_3$) δ 8.28-8.12 (m, 2H), 8.06 (dd, $J = 7.8, 1.6$ Hz, 1H), 7.72 (dd, $J = 8.0, 1.0$ Hz, 1H), 7.52-7.38 (m, 4H), 7.32 (td, $J = 7.9, 1.7$ Hz, 1H), 4.46 (q, $J = 7.1$ Hz, 2H), 1.42 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ = 162.2, 158.5, 155.7, 134.4, 132.0, 131.9, 130.4, 128.6, 128.5, 128.0, 127.6, 127.4, 127.0, 121.3, 61.5, 14.3 ppm; MS (EI, 70 eV) m/z : 77, 105, 185, 373. HRMS (ESI) m/z : calcd for $C_{18}H_{14}BrNNaO_3$ $[M+Na]^+$, 394.0049; found, 394.0053. IR (KBr): 3064, 2982, 1720, 1565, 1491, 1464, 1217, 1101, 1025, 767, 731, 690.


ethyl 2-(2-chlorophenyl)-5-phenyloxazole-4-carboxylate (3ak)



Yellow solid. M.p.: 74-75 °C. 1H NMR (400 MHz, $CDCl_3$) δ 8.12-8.05 (m, 2H), 8.03 (dd, $J = 7.5, 1.9$ Hz, 1H), 7.45 – 7.36 (m, 4H), 7.35-7.25 (m, 2H), 4.37 (q, $J = 7.1$ Hz,


2H), 1.34 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) $\delta = 162.2, 158.0, 155.7, 132.8, 131.7, 131.6, 131.1, 130.4, 128.6, 128.4, 128.0, 127.0, 126.9, 125.6, 61.5, 14.3$ ppm; MS (EI, 70 eV) m/z : 77, 105, 139, 206, 327. HRMS (ESI) m/z : calcd for $\text{C}_{18}\text{H}_{14}\text{ClNNaO}_3$ $[\text{M}+\text{Na}]^+$, 350.0554; found, 350.0566. IR (KBr): 2982, 1719, 1564, 1489, 1268, 1015, 1099, 756.

ethyl 2-(naphthalen-2-yl)-5-phenyloxazole-4-carboxylate (3al)




White solid. M.p.: 131-122 °C. ^1H NMR (400 MHz, CDCl_3) δ 9.24 (d, $J = 8.6$ Hz, 1H), 8.27 (d, $J = 7.1$ Hz, 1H), 8.20-8.11 (m, 2H), 7.96 (d, $J = 8.2$ Hz, 1H), 7.88 (d, $J = 8.1$ Hz, 1H), 7.66 (t, $J = 7.3$ Hz, 1H), 7.60 – 7.41 (m, 5H), 4.48 (q, $J = 7.1$ Hz, 2H), 1.44 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) $\delta = 162.5, 159.8, 154.8, 133.9, 131.9, 130.3, 130.2, 128.6, 128.5, 128.4, 128.3, 127.9, 127.2, 126.5, 126.0, 124.9, 123.0, 61.4, 14.4$ ppm; MS (EI, 70 eV) m/z : 77, 105, 127, 155, 343. HRMS (ESI) m/z : calcd for $\text{C}_{22}\text{H}_{17}\text{NNaO}_3$ $[\text{M}+\text{Na}]^+$, 366.1101; found, 366.1094. IR (KBr): 2983, 1717, 1551, 1490, 1265, 1222, 1097, 756.

ethyl 5-phenyl-2-(thiophen-2-yl)oxazole-4-carboxylate (3am)




Yellow solid. M.p.: 72-74 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.08 (dd, $J = 7.9, 1.7$ Hz, 2H), 7.82 (s, 1H), 7.54-7.42 (m, 4H), 7.14 (dd, $J = 4.8, 3.7$ Hz, 1H), 4.45 (q, $J = 7.1$ Hz, 2H), 1.41 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) $\delta = 162.1, 156.1, 154.5, 130.2, 129.4, 129.1, 128.7, 128.5, 128.4, 128.2, 128.0, 126.9, 61.5, 14.3$ ppm; MS (EI, 70 eV) m/z : 77, 111, 226, 299. HRMS (ESI) m/z : calcd for $\text{C}_{16}\text{H}_{13}\text{NNaO}_3$ $[\text{M}+\text{Na}]^+$, 322.0508; found, 322.0522. IR (KBr): 3079, 2982, 1720, 1594, 1492, 1209, 1093, 758, 722.

ethyl 5-phenyl-2-(pyridin-2-yl)oxazole-4-carboxylate (3an)




Yellow solid. M.p.: 126-128 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.82 (d, J = 4.5 Hz, 1H), 8.32 (d, J = 7.9 Hz, 1H), 8.19 (dd, J = 6.5, 2.9 Hz, 2H), 7.89 (td, J = 7.8, 1.2 Hz, 1H), 7.54-7.48 (m, 3H), 7.45 (dd, J = 7.2, 5.1 Hz, 1H), 4.48 (q, J = 7.1 Hz, 2H), 1.44 (t, J = 7.1 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ = 162.1, 158.4, 156.3, 150.0, 145.2, 137.1, 130.6, 130.0, 128.9, 128.3, 126.8, 125.3, 122.9, 61.5, 14.3 ppm; MS (EI, 70 eV) m/z : 79, 106, 207, 294. HRMS (ESI) m/z : calcd for $\text{C}_{17}\text{H}_{14}\text{N}_2\text{NaO}_3$ $[\text{M}+\text{Na}]^+$, 317.0897; found, 317.0891. IR (KBr): 2982, 2924, 1720, 1585, 1563, 1490, 1217, 1095, 756.

ethyl 5-(4-chlorophenyl)-2-phenyloxazole-4-carboxylate (3ba)



White solid. M.p.: 110-111 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.16-8.12 (m, 2H), 8.12-8.07 (m, 2H), 7.47 (ddt, J = 11.3, 9.2, 2.2 Hz, 5H), 4.46 (q, J = 7.1 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ = 162.2, 159.9, 153.9, 136.3, 131.2, 129.8, 128.8, 128.7, 128.6, 126.9, 126.2, 125.6, 61.6, 14.3 ppm; MS (EI, 70 eV) m/z : 77, 105, 139, 255, 327. HRMS (ESI) m/z : calcd for $\text{C}_{18}\text{H}_{14}\text{ClNNaO}_3$ $[\text{M}+\text{Na}]^+$, 350.0554; found, 350.0556. IR (KBr): 2983, 1718, 1486, 1215, 1092, 753, 712.


ethyl 5-(4-fluorophenyl)-2-phenyloxazole-4-carboxylate (3ca)



White solid. M.p.: 111-112 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.26-8.05 (m, 4H), 7.56-7.41 (m, 3H), 7.18 (t, J = 8.7 Hz, 2H), 4.46 (q, J = 7.1 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ = 165.0, 162.4 (d, J = 190 Hz), 162.3, 159.7, 154.2, 131.1, 130.8 (d, J = 9 Hz), 128.3, 128.1, 126.8, 126.3, 123.3 (d, J = 3 Hz), 115.6 (d, J = 22 Hz), 61.5, 14.3 ppm. ^{19}F NMR (376 MHz, CDCl_3) δ : -109.1 (m, 1F) ppm. MS (EI, 70 eV) m/z : 77, 95, 105, 123, 239, 311. HRMS (ESI) m/z : calcd for


$C_{18}H_{14}FNNaO_3$ $[M+Na]^+$, 334.0850; found, 334.0855. IR (KBr): 2983, 1712, 1600, 1501, 1451, 1229, 1090, 840, 705.

ethyl 5-(4-ethylphenyl)-2-phenyloxazole-4-carboxylate (3da)




Yellow oil. 1H NMR (400 MHz, $CDCl_3$) δ 8.15 (dd, J = 6.6, 3.0 Hz, 2H), 8.03 (d, J = 8.2 Hz, 2H), 7.54-7.41 (m, 3H), 7.33 (d, J = 8.2 Hz, 2H), 4.46 (q, J = 7.1 Hz, 2H), 2.72 (q, J = 7.6 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H), 1.28 (t, J = 7.6 Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ = 162.4, 159.5, 155.4, 146.9, 130.9, 128.8, 128.6, 127.9, 127.8, 126.8, 126.5, 124.5, 61.4, 28.9, 15.3, 14.3 ppm; MS (EI, 70 eV) m/z : 77, 105, 133, 249, 321. HRMS (ESI) m/z : calcd for $C_{20}H_{19}NNaO_3$ $[M+Na]^+$, 344.1257; found, 344.1259. IR (KBr): 2967, 2932, 1721, 1569, 1503, 1452, 1215, 1094.

ethyl 5-(4-tert-butylphenyl)-2-phenyloxazole-4-carboxylate (3ea)




Yellow oil. 1H NMR (400 MHz, $CDCl_3$) δ 8.16 (d, J = 3.6 Hz, 2H), 8.05 (d, J = 8.5 Hz, 2H), 7.52 (d, J = 8.5 Hz, 5H), 7.50 – 7.46 (m, 1H), 4.46 (q, J = 7.1 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H), 1.37 (s, 9H). ^{13}C NMR (100 MHz, $CDCl_3$) δ = 162.4, 155.4, 153.8, 146.9, 131.0, 128.8, 128.4, 127.9, 126.8, 126.5, 125.4, 124.3, 61.4, 43.9, 31.1, 14.3 ppm; MS (EI, 70 eV) m/z : 77, 105, 145, 334, 349. HRMS (ESI) m/z : calcd for $C_{22}H_{23}NNaO_3$ $[M+Na]^+$, 372.1570; found, 372.1576. IR (KBr): 2963, 1721, 1611, 1571, 1502, 1452, 1214, 1092, 710.

ethyl 5-(4-(methoxycarbonyl)phenyl)-2-phenyloxazole-4-carboxylate (3fa)




White solid. M.p.: 108-110 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.21 (d, *J* = 8.4 Hz, 2H), 8.19 – 8.11 (m, 4H), 7.49 (d, *J* = 5.1 Hz, 3H), 4.47 (q, *J* = 7.1 Hz, 2H), 3.95 (s, 3H), 1.43 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 166.3, 162.0, 160.3, 153.5, 131.3, 131.2, 131.1, 129.6, 129.5, 128.8, 128.3, 126.9, 126.1, 61.7, 52.3, 14.3 ppm; MS (EI, 70 eV) *m/z*: 77, 105, 135, 163, 279, 351. HRMS (ESI) *m/z*: calcd for C₂₀H₁₇NNaO₅ [M+Na]⁺, 374.0999; found, 374.998. IR (KBr): 2954, 1723, 1562, 1493, 1280, 1221, 1098, 1092, 711.

ethyl 5-(4-methoxyphenyl)-2-phenyloxazole-4-carboxylate (3ga) ⁴




Yellow solid. M.p.: 128-130 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.15 (dd, *J* = 6.6, 3.0 Hz, 2H), 8.11 (d, *J* = 8.9 Hz, 2H), 7.51-7.45 (m, 3H), 7.01 (d, *J* = 8.9 Hz, 2H), 4.46 (q, *J* = 7.1 Hz, 2H), 3.88 (s, 3H), 1.43 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 162.5, 161.2, 159.2, 155.4, 130.9, 130.2, 131.1, 128.8, 127.1, 126.8, 126.5, 119.7, 113.9, 61.4, 55.4, 14.4 ppm; MS (EI, 70 eV) *m/z*: 57, 77, 105, 135, 142, 207, 251, 323. IR (KBr): 2980, 2928, 1714, 1607, 1503, 1451, 1258, 1212, 1179, 1026, 747, 706.

ethyl 5-(4-cyanophenyl)-2-phenyloxazole-4-carboxylate (3ha)




Yellow solid. M.p.: 113-115 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.40-8.26 (m, 2H), 8.16 (dd, *J* = 7.7, 1.8 Hz, 2H), 7.81 -7.76 (m, 2H), 7.55-7.48 (m, 3H), 4.49 (q, *J* = 7.1 Hz, 2H), 1.45 (t, *J* = 7.1 Hz, 3H). ¹³C NMR (100 MHz, CDCl₃) δ = 162.0, 160.8, 152.6, 132.2, 131.2, 130.4, 129.0, 128.8, 127.1, 125.9, 118.3, 113.4, 61.9, 14.3 ppm; MS (EI, 70 eV) *m/z*: 57, 77, 130, 207, 318. HRMS (ESI) *m/z*: calcd for C₁₉H₁₄N₂NaO₃ [M+Na]⁺, 341.0897; found, 341.0897. IR (KBr): 2982, 2925, 2228, 1718, 1608, 1493, 1449, 1218, 1095, 709.

ethyl 5-(3-bromophenyl)-2-phenyloxazole-4-carboxylate (3ia)




Yellow solid. M.p.: 82-84 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.27 (s, 1H), 8.19-8.11 (m, 2H), 8.08 (d, $J = 7.9$ Hz, 1H), 7.58 (d, $J = 8.0$ Hz, 1H), 7.49 (d, $J = 5.0$ Hz, 3H), 7.36 (t, $J = 8.0$ Hz, 1H), 4.46 (q, $J = 7.1$ Hz, 2H), 1.44 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ = 162.0, 160.2, 153.1, 133.1, 131.3, 131.2, 129.9, 129.1, 129.0, 128.9, 127.1, 127.0, 126.1, 122.4, 61.7, 14.3 ppm; MS (EI, 70 eV) m/z : 77, 105, 157, 183, 301, 373. HRMS (ESI) m/z : calcd for $\text{C}_{18}\text{H}_{14}\text{BrNNaO}_3$ $[\text{M}+\text{Na}]^+$, 394.0049; found, 394.0054. IR (KBr): 2985, 1721, 1562, 1477, 1221, 1108, 748.

ethyl 2-phenyl-5-*m*-tolylloxazole-4-carboxylate (3ja)



Yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.16 (dd, $J = 6.2, 2.5$ Hz, 2H), 7.91 (d, $J = 7.3$ Hz, 2H), 7.52-7.45 (m, 3H), 7.38 (t, $J = 7.9$ Hz, 1H), 7.31-7.23 (m, 1H), 4.45 (q, $J = 7.1$ Hz, 2H), 2.45 (s, 3H), 1.42 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ = 162.3, 159.8, 155.2, 138.1, 131.1, 131.0, 129.0, 128.8, 128.3, 128.2, 127.1, 126.9, 126.5, 125.8, 61.4, 21.5, 14.3 ppm; MS (EI, 70 eV) m/z : 77, 91, 105, 119, 235, 307. HRMS (ESI) m/z : calcd for $\text{C}_{19}\text{H}_{17}\text{NNaO}_3$ $[\text{M}+\text{Na}]^+$, 330.1011; found, 330.1012. IR (KBr): 2981, 2926, 1720, 1564, 1485, 1212, 1100, 711.


ethyl 5-(3,5-dichlorophenyl)-2-phenyloxazole-4-carboxylate (3ka)



Yellow solid. M.p.: 106-108 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.19-8.11 (m, 2H), 8.07 (d, $J = 1.9$ Hz, 2H), 7.56-7.45 (m, 3H), 7.43 (t, $J = 1.8$ Hz, 1H), 4.47 (q, $J = 7.1$ Hz, 2H), 1.44 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ = 161.8, 160.4, 151.7,


135.2, 131.5, 129.9, 129.8, 129.7, 128.9, 127.0, 126.6, 125.9, 61.9, 14.2ppm; MS (EI, 70 eV) m/z : 77, 105, 145, 173, 207, 361. HRMS (ESI) m/z : calcd for $C_{18}H_{13}Cl_2NNaO_3$ $[M+Na]^+$, 384.0165; found, 384.0162. IR (KBr): 2983, 2925, 1718, 1557, 1443, 1218, 1108, 798.

ethyl 5-(naphthalen-3-yl)-2-phenyloxazole-4-carboxylate (3la)




Grey solid. M.p.: 76-78 °C. 1H NMR (400 MHz, $CDCl_3$) δ 8.67 (s, 1H), 8.23-8.16 (m, 2H), 8.13 (dd, J = 8.6, 1.7 Hz, 1H), 7.97-7.87 (m, 2H), 7.87-7.81 (m, 1H), 7.57-7.45 (m, 5H), 4.48 (q, J = 7.1 Hz, 2H), 1.43 (t, J = 7.1 Hz, 3H). ^{13}C NMR (100 MHz, $CDCl_3$) δ = 162.4, 159.9, 155.1, 133.9, 132.8, 131.1, 129.0, 128.9, 128.8, 128.6, 128.0, 127.7, 127.5, 126.9, 126.7, 126.5, 125.1, 124.5, 61.5, 14.4ppm; MS (EI, 70 eV) m/z : 77, 105, 127, 155, 343. HRMS (ESI) m/z : calcd for $C_{20}H_{19}NNaO_3$ $[M+Na]^+$, 344.1257; found, 344.1271. IR (KBr): 3059, 2983, 2929, 1719, 1562, 1489, 1211, 1094, 751.

ethyl 5-(2-bromophenyl)-2-phenyloxazole-4-carboxylate (3ma)




Yellow solid. M.p.: 100-102 °C. 1H NMR (400 MHz, $CDCl_3$) δ 8.20-8.12 (m, 2H), 7.72 (dd, J = 8.0, 1.0 Hz, 1H), 7.57 (dd, J = 7.6, 1.7 Hz, 1H), 7.52-7.33 (m, 5H), 4.32 (q, J = 7.1 Hz, 2H), 1.24 (t, J = 7.1 Hz, 4H). ^{13}C NMR (100 MHz, $CDCl_3$) δ = 161.5, 161.1, 153.7, 133.1, 132.5, 131.6, 131.2, 130.8, 129.3, 128.8, 127.0, 126.9, 126.4, 123.9, 61.3, 14.0ppm; MS (EI, 70 eV) m/z : 77, 105, 142, 264, 292, 371. HRMS (ESI) m/z : calcd for $C_{18}H_{14}BrNNaO_3$ $[M+Na]^+$, 394.0049; found, 394.0056. IR (KBr): 2982, 2926, 1730, 1616, 1560, 1475, 1197, 1100, 757.

ethyl 5-methyl-2-phenyloxazole-4-carboxylate (3na) ⁵




Yellow oil. ^1H NMR (400 MHz, CDCl_3) δ 8.13 – 8.01 (m, 2H), 7.49-7.40 (m, 3H), 4.43 (q, $J = 7.1$ Hz, 2H), 2.71 (s, 3H), 1.42 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ = 162.5, 159.7, 156.1, 130.7, 128.8, 128.7, 126.7, 126.6, 61.0, 14.4, 12.2ppm; MS (EI, 70 eV) m/z : 77, 105, 185, 231. IR (KBr): 2984, 2924, 1720, 1615, 1563, 1486, 1102, 913, 744.

methyl 2,5-diphenyloxazole-4-carboxylate (3oa) ⁶



White solid. M.p.: 71-73 °C. ^1H NMR (400 MHz, CDCl_3) δ 8.14 (dd, $J = 8.1, 1.4$ Hz, 4H), 7.52-7.44 (m, 6H), 3.97 (s, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ = 171.2, 162.7, 123.6, 131.1, 130.4, 130.2, 128.9, 128.5, 128.0, 127.0, 126.8, 126.3, 52.4ppm; MS (EI, 70 eV) m/z : 77, 105, 165, 279. IR (KBr): 3063, 2950, 1723, 1564, 1489, 1443, 1223, 1102, 711, 689.

ethyl 5-(tert-butyl)-2-phenyloxazole-4-carboxylate (3pa) ¹




Green oil. ^1H NMR (400 MHz, CDCl_3) ^1H NMR (400 MHz, CDCl_3) δ 8.01-7.94 (m, 2H), 7.41-7.35 (m, 3H), 4.36 (q, $J = 7.1$ Hz, 2H), 1.45 (s, 9H), 1.36 (t, $J = 7.1$ Hz, 3H). ^{13}C NMR (100 MHz, CDCl_3) δ = 165.5, 162.5, 157.8, 130.6, 128.7, 127.6, 126.7, 126.6, 61.2, 33.5, 28.2, 14.3ppm; MS (EI, 70 eV) m/z : 106, 212, 258, 273. IR (KBr): 2988, 1764, 1567, 1454, 1373, 1242.


F. Reference

1. C. Wan, J. Zhang, S. Wang, J. Fan and Z. Wang, *Org. Lett.*, 2010, **12**, 2338.
2. C. Verrier, C. Fiol-Petit, C. Hoarau and F. Marsais. *Org. Biomol. Chem.*, 2011, **9**, 6215.
3. L. Théveau, C. Verrier, P. Lassalas, T. Martin, G. Dupas, O. Querolle, L. Van Hijfte, F. Marsais and C. Hoarau. *Chem. Eur. J.*, 2012, **18**, 1848.
4. S. Vijay Kumar, B. Saraiah, N. C. Misra and H. Ila. *J. Org. Chem.*, 2012, **77**, 10752.
5. M. A. Kuznetsov and V. V. Voronin. *Chem. Heterocycl. Compd.*, 2011, **47**, 173.
6. P. M. T. Ferreira, L. S. Monteiro and G. Pereira. *Eur. J. Org. Chem.*, 2008, 4676.


G. NMR Spectra




3aa-H




3aa-C




3ab-H




3ab-C




3ab-F




3ac-H




3ac-C




3ad-H




3ad-C




3ae-H




3ae-C




3ae-F




3af-H




3af-C




3ag-H




3ag-C




3ah-H




3ah-C




3ai-H




3ai-C




3aj-H




3aj-C




3ak-H




3ak-C




3al-H




3al-C




3am-H




3am-C




3an-H




3an-C




3ba-H




3ba-C




3ca-H




3ca-C




3ca-F




3da-H




3da-C




3ea-H




3ea-C




3fa-H




3fa-C




3ga-H




3ga-C




3ha-H




3ha-C




3ia-H




3ia-C




3ja-H




3ja-C




3ka-H




3ka-C




3la-H




3la-C




3ma-H




3ma-C




3na-H




3na-C




30a-H



30a-C




3pa-H



3pa-C

H. X-ray Crystallographic Analysis of 3ka



Summary of Data CCDC 982238

Compound Name:

Formula: C₁₈ H₁₃ Cl₂ N₁ O₃

Unit Cell Parameters: a 7.4219(15) b 9.3714(19) c 13.520(3) P-1